| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Siobhan Gee, Fiona Gaughran, James MacCabe, Sukhi Shergill, Eromona Whiskey, David Taylo. Management of clozapine treatment during the COVID-19 pandemic. Therapeutic advances in psychopharmacology. vol 10. 2020-09-28. PMID:32542111. |
clozapine is the only available treatment for refractory schizophrenia but its use involves frequent physical contact with healthcare workers for the purpose of mandatory blood monitoring. |
2020-09-28 |
2023-08-13 |
Not clear |
| Eromona Whiskey, Shirley Yuen, Emma Khosla, Susan Piper, David O'Flynn, David Taylo. Resolution without discontinuation: heart failure during clozapine treatment. Therapeutic advances in psychopharmacology. vol 10. 2020-09-28. PMID:32547730. |
clozapine is an atypical antipsychotic recommended for patients with treatment-resistant schizophrenia whose illness has not responded adequately to treatment despite the sequential use of at least two different antipsychotic drugs at therapeutic doses. |
2020-09-28 |
2023-08-13 |
Not clear |
| Remiko Kobayashi, Yasunori Oda, Ryunosuke Hayatsu, Nozomi Ohki, Misa Akutsu, Takahiro Oiwa, Hideki Komatsu, Tomihisa Niitsu, Tsuyoshi Sasaki, Masaomi Iy. Successful rechallenge with paliperidone after clozapine treatment for a patient with dopamine supersensitivity psychosis. SAGE open medical case reports. vol 8. 2020-09-28. PMID:32551117. |
we describe the case of a 49-year-old japanese male patient successfully treated with a paliperidone rechallenge following 2-year treatment with clozapine for treatment-resistant schizophrenia. |
2020-09-28 |
2023-08-13 |
Not clear |
| Solomon Teferr. Initiating clozapine treatment service and characteristics of clozapine-treated patients in a general hospital in Addis Ababa, Ethiopia. The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa. vol 26. 2020-09-28. PMID:32670632. |
at least one-third of patients with schizophrenia suffer from treatment-resistant schizophrenia needing treatment with clozapine. |
2020-09-28 |
2023-08-13 |
Not clear |
| Catherine Gisi, Anamaria Munteanu, Lawrence Ku, Samuel French, Michael Fleischman, Viktor Eysselei. Atypical Presentation of Acquired Hypoganglionosis in a Patient Taking Clozapine. Case reports in gastrointestinal medicine. vol 2020. 2020-09-28. PMID:32670642. |
clozapine is an atypical antipsychotic used to treat refractory schizophrenia that is well known for its side effects including agranulocytosis and gastrointestinal dysmotility. |
2020-09-28 |
2023-08-13 |
Not clear |
| Xavier Boland, Luiz Dratc. Clozapine in the Time of COVID-19. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 18. issue 3. 2020-09-28. PMID:32702224. |
clozapine is the most effective antipsychotic for treatment resistant schizophrenia but adverse reactions to clozapine include neutropenia. |
2020-09-28 |
2023-08-13 |
Not clear |
| Xavier Boland, Luiz Dratc. Clozapine in the Time of COVID-19. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 18. issue 3. 2020-09-28. PMID:32702224. |
we report on two actively psychotic patients with treatment resistant schizophrenia who required admission to our inner-london acute psychiatric unit during the covid-19 pandemic and who were treated with clozapine. |
2020-09-28 |
2023-08-13 |
Not clear |
| Olivia Morrow, Lucy Gibson, Manraj Bhamra, Anthony S David, Sotirios Posporeli. G-CSF mediated neutrophil augmentation in a unique case of comorbid idiopathic Parkinson's disease and treatment-resistant schizophrenia on clozapine. Therapeutic advances in psychopharmacology. vol 10. 2020-09-28. PMID:32973999. |
g-csf mediated neutrophil augmentation in a unique case of comorbid idiopathic parkinson's disease and treatment-resistant schizophrenia on clozapine. |
2020-09-28 |
2023-08-13 |
Not clear |
| Chieh-Hsin Lin, Chun-Yuan Lin, Hong-Song Wang, Hsien-Yuan Lan. Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia. Scientific reports. vol 9. issue 1. 2020-09-23. PMID:30846868. |
long-term use of clozapine is protective for bone density in patients with schizophrenia. |
2020-09-23 |
2023-08-13 |
Not clear |
| Chieh-Hsin Lin, Chun-Yuan Lin, Hong-Song Wang, Hsien-Yuan Lan. Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia. Scientific reports. vol 9. issue 1. 2020-09-23. PMID:30846868. |
previous cross-section study suggests that clozapine treatment may benefit bmd of women with schizophrenia. |
2020-09-23 |
2023-08-13 |
Not clear |
| Chieh-Hsin Lin, Chun-Yuan Lin, Hong-Song Wang, Hsien-Yuan Lan. Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia. Scientific reports. vol 9. issue 1. 2020-09-23. PMID:30846868. |
this prospective study compared clozapine and non-clozapine antipsychotics in long-term effects on bmd among both men and women with schizophrenia. |
2020-09-23 |
2023-08-13 |
Not clear |
| Chieh-Hsin Lin, Chun-Yuan Lin, Hong-Song Wang, Hsien-Yuan Lan. Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia. Scientific reports. vol 9. issue 1. 2020-09-23. PMID:30846868. |
this longitudinal study suggests that long-term clozapine treatment may protect bmd compared to prolactin-raising and non-clozapine prolactin-sparing antipsychotics among patients with schizophrenia. |
2020-09-23 |
2023-08-13 |
Not clear |
| Dan Siskind, Faraz Honarparvar, Alkomiet Hasan, Elias Wagner, Surabhi Sinha, Stacy Orr, Steve Kisel. rTMS for clozapine refractory schizophrenia - A systematic review and pairwise meta-analysis. Schizophrenia research. vol 211. 2020-09-22. PMID:31301880. |
rtms for clozapine refractory schizophrenia - a systematic review and pairwise meta-analysis. |
2020-09-22 |
2023-08-13 |
Not clear |
| Sakir Gica, Ahsen Buyukavsar, Burc Cagri Poyraz, Huseyin Gule. The clinical correlation and predictive value of electrophysiological variables on clinical response to clozapine in patients with treatment-resistant schizophrenia. Schizophrenia research. vol 211. 2020-09-21. PMID:31331783. |
the clinical correlation and predictive value of electrophysiological variables on clinical response to clozapine in patients with treatment-resistant schizophrenia. |
2020-09-21 |
2023-08-13 |
Not clear |
| Orwa Albitar, Sabariah Noor Harun, Hadzliana Zainal, Baharudin Ibrahim, Siti Maisharah Sheikh Ghadz. Population Pharmacokinetics of Clozapine: A Systematic Review. BioMed research international. vol 2020. 2020-09-21. PMID:31998804. |
clozapine is a second-generation antipsychotic drug that is considered the most effective treatment for refractory schizophrenia. |
2020-09-21 |
2023-08-13 |
Not clear |
| V V Kravtsov, I A Filippov, E E Vaiman, N A Shnayder, R F Nasyrov. [Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 120. issue 7. 2020-09-17. PMID:32790988. |
a systematic review of association studies on the role of single nucleotide variants (snvs) of the dopaminergic system genes on the effectiveness of clozapine in schizophrenia has been perfromed. |
2020-09-17 |
2023-08-13 |
Not clear |
| Piotr Jahołkowski, Julita Niewiadomska, Jacek Wciórka, Mirosław Kowalski, Piotr Świta. Clozapine-induced myocarditis during co-administration of valproate: A case report. Psychiatria polska. vol 53. issue 5. 2020-09-16. PMID:31955181. |
in this paper, we present a case of a 22-year-old male patient with refractory schizophrenia who developed cimduring low-dose clozapine treatment with co-administration of valproate and risperidone. |
2020-09-16 |
2023-08-13 |
Not clear |
| Mark James Ponsford, Rachael Steven, Kathyrn Bramhall, Mathew Burgess, Sonali Wijetilleka, Emily Carne, Frances McGuire, Colin R Price, Mo Moody, Soha Zouwail, Tayyeb Tahir, Daniel Farewell, Tariq El-Shanawany, Stephen R A Jolle. Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID). Journal of clinical pathology. vol 73. issue 9. 2020-08-31. PMID:32094276. |
an association between antibody deficiency and clozapine use in individuals with schizophrenia has recently been reported. |
2020-08-31 |
2023-08-13 |
Not clear |
| Thinh Nguyen, Jasmine Mordecai, Felice Watt, Jacqueline Frayn. Obstetric and neonatal outcomes of clozapine exposure in pregnancy: a consecutive case series. Archives of women's mental health. vol 23. issue 3. 2020-08-25. PMID:31203441. |
clozapine is an effective antipsychotic that can lead to symptom resolution and functional recovery in patients with schizophrenia. |
2020-08-25 |
2023-08-13 |
Not clear |
| Rajendra P Shukla, Hadar Ben-Yoa. A Chitosan-Carbon Nanotube-Modified Microelectrode for In Situ Detection of Blood Levels of the Antipsychotic Clozapine in a Finger-Pricked Sample Volume. Advanced healthcare materials. vol 8. issue 15. 2020-08-19. PMID:31240866. |
the antipsychotic clozapine is the most effective medication available for schizophrenia and it is the only antipsychotic with a known efficacious clinical range. |
2020-08-19 |
2023-08-13 |
human |